Hunan Hansen Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002412.SZ

Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2023: USD 50.06 M

Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities is USD 50.06 M for the year ending December 31, 2023, a -9.14% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2022 was USD 55.10 M, a -0.28% change year over year.
Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2021 was USD 55.26 M, a 31.91% change year over year.
Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2020 was USD 41.89 M, a -13.32% change year over year.
Hunan Hansen Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2019 was USD 48.32 M, a -20.37% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shenzhen Stock Exchange: 002412.SZ

Hunan Hansen Pharmaceutical Co., Ltd.

CEO	Mr. Zhengqing Liu
IPO Date	May 25, 2010
Location	China
Headquarters	No. 2688, Yincheng Avenue
Employees	1,536
Sector	Health Care
Industries Pharmaceuticals

Description

Hunan Hansen Pharmaceutical Co., Ltd. produces and sells Chinese and chemical medicine preparations in China and internationally. It provides medicines in injection, oral liquid, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. The company is based in Yiyang, China.

Key trends

Past 5 years